This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

For the treatment of Invasive Aspergillosis and also for the treatment of Mucormycosis in patients for whom amphotericin B is inappropriate1

References:
  1. CRESEMBA Summary of Product Characteristics.
  2. Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voricanazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE); a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769.
  3. Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837.

CRESEMBA® Mode of Action

CRESEMBA® contains the active substance isavuconazonium sulfate. Once hydrolysed into its active form, isavuconazole, it induces fungal cell death by inhibiting the production of fungal cell membrane components.

CRESEMBA® in Invasive Aspergillosis

The SECURE study was undertaken to compare the efficacy and safety of intravenous and oral formulations of isavuconazole to voriconazole for the primary treatment of invasive aspergillosis2.

Study Design

Efficacy

CRESEMBA® in Mucormycosis in patients for whom amphotericin B is inappropriate

The VITAL trial was undertaken to assess the efficacy and safety of isavuconazole for treatment of mucormycosis and to compare its efficacy with amphotericin B in a matched case-control analysis3.

Study Design

Efficacy

Medical Education Events

Join us at one of our upcoming Medical Education events by registering your interest

Register your interest

Antifungal Stewardship

Discover resources designed to support you in adopting antifungal stewardship in your practice.

Find out more

Explore more

Safety Profile

Understand more about the safety profile of CRESEMBA

View safety profile

Dosing

Dosing recommendations for CRESEMBA

Access dosing information

Access Pfizer

Consider CRESEMBA® for the treatment of invasive aspergillosis and mucormycosis. For further information, contact your Pfizer representative

Get your questions answered now


References:
  1. CRESEMBA GB Summary of Product Characteristics.
  2. Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voricanazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE); a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769.
  3. Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837.
PP-CRB-GBR-1201. August 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No